Clinical Trial Imaging Endpoint Process Standards¶
U.S. Food and Drug Administration. (2018). Clinical Trial Imaging Endpoint Process Standards: Guidance for Industry.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Mechanisms¶
- Blind Revalidation
- Its strength is removing the confirmation and anchoring bias that a same-evidence re-read otherwise inherits: a reviewer who cannot see the first verdict evaluates the substance on its merits, so their agreement is worth something and their disagreement is a genuine signal.
This sourceRecommends independent, blinded image-reading procedures with locked original outcomes and prespecified inter-reader metrics, treating discordance and adjudication rates as informative about interpretive subjectivity.
- Its strength is removing the confirmation and anchoring bias that a same-evidence re-read otherwise inherits: a reviewer who cannot see the first verdict evaluates the substance on its merits, so their agreement is worth something and their disagreement is a genuine signal.
Verification¶
Does it exist? Not checked yet. This entry carries no identifier to resolve. It was extracted from the citation as written in the article, normalized, and deduplicated against the rest of the registry.
Does it back the claim? Not recorded. The single citation of this work carries no recorded support check.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:097966403492 · see in the full table